Skip to content
2000
Volume 14, Issue 9
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

The outstanding physiological functions of glucagon-like peptide-1 make it a promising drug candidate for blood glucose regulation in type 2 diabetes. However, the short half-life of GLP-1 limited its widely clinical utility due to the rapid degradation by dipeptidyl peptidase IV (DPP-IV) and renal clearance. Therefore, stabilisation of glucagon-like peptide-1 is critical for the use of this peptide in drug development. Scientists in pharmaceutical companies have contributed in years to obtain long-acting or sustained GLP-1 derivatives which are reviewed in this report.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/1389201014666131227120546
2013-10-01
2025-10-07
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/1389201014666131227120546
Loading

  • Article Type:
    Research Article
Keyword(s): GLP-1; Long-acting analogs; Type 2 diabetes
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test